US approves pancreatic cancer treatment that targets ‘undruggable’ proteins

A first-of-its-kind drug has received approval from the US Food and Drug Administration (FDA) for treatment of metastatic pancreatic cancer. The new drug, Rasonque (daraxonrasib), blocks Ras proteins, which are linked to many cancer types and were once thought to be ‘undruggable’.